New research reveals that patients who discontinue new GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight at a significantly accelerated pace than those who end traditional diet and exercise plans.
Findings released in a leading health publication points out that while overweight people often shed a large proportion of their total mass while on the medication, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"Users using these drugs should be informed of the danger of fast rebound weight gain when the treatment is stopped," warns expert Dr. Susan Jebb.
This pace of regain implies a return to original mass within about one and a half years.
Comparing Approaches
The research, which reviewed dozens of studies involving over 9,000 of participants, contrasted the results of the injectable medications with older methods.
Researchers note that individuals who lose weight through dieting generally experience a more gradual creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists suggest the mode of action of the injections accounts for the accelerated regain.
The injections imitate a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Issue?
Medical guidelines advise the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals contend that, considering the likelihood of weight regain, the therapy is often ongoing.
This opinion is echoed by drug manufacturers, who note that the findings "underscore the persistent nature of obesity," akin to managing diseases like hypertension.
Patient Accounts
Individuals who have stopped the jabs report a intense resurgence of hunger.
"I experienced a trigger that goes on and you become starving," said a patient.
This difficulty is worsened if patients have not developed lasting dietary or behavioural modifications during treatment.
Growing Interest
Survey data indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with demand remaining high.
- Adoption is greater among women than men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Ultimately, clinicians stress that while these medications are powerful agents for weight loss, they are not a standalone solution and long-term success likely depends on ongoing behavioural support.
